Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin’s Lymphoma

MLA

Marie-Odile Petillon, et al. “Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (HA20), in Non-Hodgkin’s Lymphoma.” Blood, vol. 106, Nov. 2005, p. 2428. EBSCOhost, https://doi.org/10.1182/blood.v106.11.2428.2428.

APA

Marie-Odile Petillon, Amina Bahkti, John P. Leonard, Nick Teoh, Puja Sapra, Morton Coleman, Bertrand Coiffier, Ivan Horak, William A. Wegener, David M. Goldenberg, & Franck Morschhauser. (2005). Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Non-Hodgkin’s Lymphoma. Blood, 106, 2428. https://doi.org/10.1182/blood.v106.11.2428.2428

Chicago

Marie-Odile Petillon, Amina Bahkti, John P. Leonard, Nick Teoh, Puja Sapra, Morton Coleman, Bertrand Coiffier, et al. 2005. “Initial Safety and Efficacy Results of a Second-Generation Humanized Anti-CD20 Antibody, IMMU-106 (HA20), in Non-Hodgkin’s Lymphoma.” Blood 106 (November): 2428. doi:10.1182/blood.v106.11.2428.2428.